SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares - May 2020

Sanofi: Information concerning the total number of voting rights and shares - May 2020

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,507,692,222 €

Registered office : 54, rue La Boétie – 75008 Paris – France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date  



Total number of

issued shares



  		Number of real

voting rights

(excluding treasury shares) 		Theoretical number of

voting rights

(including treasury shares)*
May 31, 2020 1,256,103,874 1,406,258,458 1,408,853,379

*  Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

Europe Tel: 45  US Tel: 0

e-mail:



 



Media Relations Department

Tel: 46

 e-mail:



 

 

Attachment

EN
19/06/2020

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Sanofi finalise l’acquisition du DR-0201

Communiqué de presse : Sanofi finalise l’acquisition du DR-0201 Sanofi finalise l’acquisition du DR-0201 Paris, le 27 mars 2025. Sanofi annonce la finalisation de l’acquisition du DR-0201, un anticorps bispécifique ciblé qui engage les cellules myéloïdes, à Dren Bio, Inc., société biopharmaceutique privée au stade clinique. Cette acquisition renforce l’ambition de Sanofi de devenir le leader mondial de l’immunologie et élargit son portefeuille de R&D en immunologie, déjà parmi les plus avancés du secteur. Le DR-0201, désormais SAR448501, a démontré sa capacité à induire une déplétio...

May 27, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi completes acquisition of DR-0201

Press Release: Sanofi completes acquisition of DR-0201 Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its , a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition bolsters Sanofi’s ambition to become the foremost immunology company and broadens the company’s leading immunology pipeline. DR-0201, now named SAR448501, has shown robust B-cell depletion in pre-clinical and early clinical studies. The potential first-in-class targeted bispecific myeloid cell engage...

May 27, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a ne...

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi’s four ...

May 21, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Sanofi va acquérir Vigil Neuroscience, Inc. et ...

Communiqué de presse : Sanofi va acquérir Vigil Neuroscience, Inc. et ajouter un nouveau médicament expérimental pour le traitement de la maladie d’Alzheimer à son portefeuille en neurologie Sanofi va acquérir Vigil Neuroscience, Inc. et ajouter un nouveau médicament expérimental pour le traitement de la maladie d’Alzheimer à son portefeuille en neurologie Paris, le 22 mai 2025. Sanofi annonce aujourd’hui avoir conclu un accord en vue de l’acquisition de Vigil Neuroscience, Inc. (ci-après « Vigil »), une société de biotechnologie cotée en bourse spécialisée dans le développement de médi...

May 21, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - April 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry und...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch